Biovail Cardizem XL NDA Highlights Nighttime Dose For Cardiac AE Prevention
Executive Summary
Biovail's NDA for hypertension agent Cardizem XL (diltiazem) highlights nighttime dosing aimed at achieving maximum drug levels between 6 a.m. and noon, when the majority of adverse cardiac events take place.
You may also be interested in...
Biovail Cardizem LA Bedtime/Morning Dosing Flexibility Included In Label
Biovail will launch Cardizem LA on April 2 following FDA's Feb. 6 approval of the "graded-release," once-daily diltiazem for hypertension
Biovail Cardizem LA Bedtime/Morning Dosing Flexibility Included In Label
Biovail will launch Cardizem LA on April 2 following FDA's Feb. 6 approval of the "graded-release," once-daily diltiazem for hypertension
Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July
Biovail expects results from a Phase III trial of several fixed-dose combinations of Vasotec and Cardizem XL in the first half of the year